PI3K/AKT pathway activation and therapeutic consequences in breast cancer;A PI3K/AKT szignálút aktivációjának mechanizmusai és terápiás következményei emlödaganatokban

Magyar Onkologia

Volumn 59, Issue 4, 2015, Pages 346-351

  Judit, Olasz ^a   Zoltán, Doleschall ^a   Zsuzsanna, Dunai ^a   András, Pazsitka ^a   Orsolya, Csuka ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

Author keywords

FGFR1; PI3K AKT pathway; PTEN; Targeted therapy; Therapy resistance

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; MESSENGER RNA; PD 166866; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE CATALYTIC SUBUNIT ALPHA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; AUTOCRINE EFFECT; BREAST CANCER; BREAST CARCINOGENESIS; CANCER PATIENT; CELL PROLIFERATION; DNA METHYLATION; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVATION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE EXPRESSION; GENE INACTIVATION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; MAJOR CLINICAL STUDY; MCF-10A CELL LINE; MICROARRAY ANALYSIS; PI3K/AKT SIGNALING; PROGESTERONE RECEPTOR POSITIVE BREAST CANCER; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN DEFICIENCY; PROTEIN DEPLETION; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; WILD TYPE;

EID: 84985923587     PISSN: 00250244     EISSN: 20600399     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Sørlie, T, Perou, C M, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS 98:10869-10874, 2001
2. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441:424-430, 2006
3. Stephens PJ, Tarpey PS, Davies H, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 486:400-404, 2012
4. The Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature 490:61-70, 2012
5. Saal LH, Holm K, Maurer M, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65:2554-2559, 2005
6. Pérez-Tenorio G, Alkhori L, Olsson B, et al. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res 13:3577-3584, 2007
7. Marty B, Maire V, Gravier E, et al. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res 10:R101, 2008
8. Khan S, Kumagai T, Vora J, et al. PTEN promoter is methylated in a proportion of invasive breast cancers. Int J Cancer 112:407-410, 2004
9. Sanchez CG, Ma CX, Crowder RJ, et al. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res 13:R21, 2011
10. Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12: 395-402, 2007
11. Jensen JD, KnoopA, Laenkholm AV, et al. PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. Ann Oncol 23:2034-2042, 2012
12. Penault-Llorca F, Bertucci F, Adélaïde J, et al. Expression of FGF and FGF receptor genes in human breast cancer. Int J Cancer 61:170-176, 1995
13. Courjal F, Cuny M, Simony-Lafontaine J, et al. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. Cancer Res 57:4360-4367, 1997
14. Xian W, Schwertfeger KL, Vargo-Gogola T, et al. Pleiotropic effects of FGFR1 on cell proliferation, survival, and migration in a 3D mammary epithelial cell model. J Cell Biol 171:663-673, 2005
15. Acevedo VD, Ittmann M, Spencer DM. Paths of FGFR-driven tumorigenesis. Cell Cycle 8:580-588, 2009
16. Turner N, Pearson A, Sharpe R, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 70:2085-2094, 2010
17. Sharpe R, Pearson A, Herrera-Abreu MT, et al. FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo. Clin Cancer Res 17:5275-5286, 2011
18. Péter I, Számel I, Péley G. Az ösztrogénteceptor-béta expressziója invazív emlötumorokban. Magyar Onkológia 48:63-69, 2004
19. Cserni G, Kálmán E, Kulka J, et al. HER2 immunhisztokémiai vizsgálatok minöségellenörzése. Egy magyarországi körvizsgálat eredményei. Magyar Onkológia 51:23-29, 2007
20. NHS Cancer Screening Programmes and The Royal College of Pathologists. Pathology Reporting of Breast Disease. NHSBSP Publication No 58, 2005. http://www.cancerscreening.nhs.uk/breastscreen/publications/nhsbsp58.html
21. Eads CA, Danenberg KD, Kawakami K, et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 28:E32, 2000
22. O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res 16:3670-3683, 2010
23. Stemke-Hale K, Gonzales-Angulo AM, Lluch A, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68:6084-6091, 2008
24. Beelen K, Opdam M, Severson TM, et al. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients. Breast Cancer Res 16:R13, 2014
25. Razis E, Bobos M, Kotoula V, et al. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Cancer Res Treat 128:447-456, 2011
26. André F, O'Regan R, Ozguroglu M, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 15:580-591, 2014
27. Chakrabarty A, Bhola NE, Sutton C, et al. Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors. Cancer Res 73:1190-2000, 2013
28. Rexer BN, Chanthaphaychith S, Dahlman K, et al. Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells. Breast Cancer Res 16:R9, 2014
29. Xiang T, Jia Y, Sherris D, et al. Targeting the Akt/mTOR pathway in Brca1-deficient cancers. Oncogene 30:2443-2450, 2011
30. Shah SP, Roth A, Goya R, et al. The clonal and mutational evolution spectrum of primary triple negative breast cancers. Nature 486:395-399, 2012
31. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121:2750-2767, 2011